Brokerage firm JP Morgan Maintains its rating on Enanta Pharmaceuticals Inc(NASDAQ:ENTA). In a research note issued to the investors, the brokerage major Lowers the price-target to $26.00 per share. The shares have been rated Overweight. The rating by JP Morgan was issued on Aug 9, 2016.
Enanta Pharmaceuticals Inc (ENTA) made into the market gainers list on Wednesdays trading session with the shares advancing 0.22% or 0.05 points. Due to strong positive momentum, the stock ended at $23.2, which is also near the day’s high of $23.27. The stock began the session at $23.09 and the volume stood at 2,15,074 shares. The 52-week high of the shares is $43.08 and the 52 week low is $16.75. The company has a current market capitalization of $442 M and it has 1,90,35,910 shares in outstanding.
Enanta Pharmaceuticals Inc(ENTA) last announced its earnings results on Aug 8, 2016 for Fiscal Year 2016 and Q3.Company reported revenue of $13.98M. Analysts had an estimated revenue of $12.78M. Earnings per share were $-0.06. Analysts had estimated an EPS of $-0.10.
Several Insider Transactions has been reported to the SEC. On May 12, 2016, Nathaniel S. Gardiner (Sr. VP & General Counsel) purchased 500 shares at $24.44 per share price.Also, On Feb 17, 2016, Terry Vance (director) purchased 2,000 shares at $27.04 per share price.On Nov 25, 2015, Paul J Mellett (Treasurer and CFO) sold 6,000 shares at $31.23 per share price, according to the Form-4 filing with the securities and exchange commission.
Enanta Pharmaceuticals Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV) as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC). The Company is involved in a program to develop nucleotide inhibitors to HCV NS5B polymerase. In its NASH program the Company is developing agonists of the farnesoid X receptor or FXR that are designed to bind to that receptor and then trigger a response from it. The Company is also engaged in a program in PBC another disease of the liver that can result in liver damage liver failure or hepatocellular carcinoma. Its pipeline of products includes Paritaprevir ABT-493 EDP-239 ABT-494 and EDP-494.